Innocrin is a privately held, clinical-stage pharmaceutical company that discovers and develops novel, best-in-class oral selective inhibitors of CYP17 lyase, a validated target for the treatment of advanced breast and prostate cancer.

Product Development

We are currently focused on the clinical development of the best in class oral selective CYP17 lyase and androgen receptor (AR) inhibitor, seviteronel (INO-464), for the treatment of advanced breast cancer and castration-resistant prostate cancer (CRPC). We seek to provide patients, physicians, partners and investors with up-to-date and accessible information regarding our products and the company.


We are developing oral, conveniently administered CYP17 lyase inhibitors for the benefit of patients with hormonally-driven diseases or conditions.